Experimental study of anti-inflammatory activity of the new combined with drug urolytolytic action.

Authors

  • T. I. Iermolenko

DOI:

https://doi.org/10.26641/2307-0404.2015.2.45643

Keywords:

urolithiasis, inflammation, biologically active substances, flavonoids, anti-inflammatory activity

Abstract

Herbal medicines provide their versatile complex influence on the course of the pathological process in the kidneys due to biologically active compounds. Specifically, they cause the direct impact on the concrements formation. The search of drugs which would contain high biological compounds of plant origin is an actual issue of modern pharmacology. The aim of investigation was to study the anti-inflammatory activity of the new combined drug of urolytolytic action, which includes the total plant extract and succinate buffer complex. Materials and methods: aseptic exudative inflammation was caused by  subplantar introduction of 0,1 ml of 1% solution of λ-karahenin in the right hind paw of rats, the investigated drug was administered at doses 1, 2 and 4 ml/kg. The influence of the studied drug was evaluated in terms of swelling limbs volume. It is shown that the severity of antiexudative action of flarosukcinehad dose-dependent nature, increasing from dose of 1,0 ml/kg to 2,0 ml/kg (by 5,5%). Further dose increase to 4,0 ml/kg, was not defined by significant increase of activity. Anti-inflammatory activity of the drug ranged from 25 to 33%, which can be regarded as quite distinct, since in pharmacological study of anti-inflammatory drugs pharmacological activity level of at least 20%is significant.

Author Biography

T. I. Iermolenko

Kharkiv National Medical University
Department of Pharmacology and Medical recipes
Lenin av., 4, Kharkov, 61022, Ukraine

References

Toropova AA, Batotcirenova ET, Olejnikov DN. [Antioxidant activity of dry groundwater bodies extract Astragalus membranaceus and its fractions]. Siberian Medical Journal. 2012;114(7):107–9. Russian. 2. Stefanov AV. [Preclinical drugs studies: method. rivers.]. 2002;528. Russian. 3. Makarova MN. [Bioavailability and metabolism of flavonoids]. Experimental and Clinical Pharmacology. 2011;74(6):33–40. Russian. 4. Popov AM, Krivoshapko ON, Artyukova AA. [Mecha¬nisms of protective pharmacological activity of flavonoids]. Biopharmaceutical magazine. 2012;4(4):27–41. Russian. 5. Rebrov OU. [Statistical analysis of medical data. Application software package Statistica (4th ed.)]. 2006;312. Russian. 6. Rybolovlev YR, Rybolovlev RS. [Dosage of sub¬stances for mammalian by constants of biological acti¬vity]. 1979;6:1513–16. Russian. 7. Tareeva IE. [Kidney Disease: A Guide for doctors]. 2000;413–21. Russian. 8. Chekman ІS. [Fіtotherapy: experimental-clinic aspect]. Eksperimentalna i klіnіchna medicine. 2007;1:11–14. Ukrainian. 9. European convention for the protection of vertebrate animals used for experimental and other scien¬tific purpose. Council of Europe, Strasbourg. 1986;52. 10. Cazarolli LH, Zanatta L, Alberton EH. Fla¬vo¬noids: prospective drug candidates. Mini Reviews in Medicinal Chemistry. 2008;8(13):1429–40.

Downloads

Published

2015-06-08

How to Cite

1.
Iermolenko TI. Experimental study of anti-inflammatory activity of the new combined with drug urolytolytic action. Med. perspekt. [Internet]. 2015Jun.8 [cited 2024Mar.28];20(2):25-9. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/45643

Issue

Section

THEORETICAL MEDICINE